Quick answer: California requires synchronous documented good faith examinations for initial compounded GLP-1 prescribing, strict Corporate Practice of Medicine enforcement, and PC-MSO entity structure for non-physician investors. Nurse practitioners require a standardized procedure with a supervising physician to prescribe compounded medications.
California is the largest compounded GLP-1 market in the US by patient volume. The Medical Board of California enforces strict CPOM doctrine, and the Board of Pharmacy actively audits 503A and 503B compounding pharmacies serving California patients.
The five clinical and regulatory parameters that determine whether a compounded GLP-1 program is defensible under California board scrutiny.
Synchronous real-time audio and video is required for initial visits prescribing controlled substances or compounded medications. Asynchronous-only GFE is not defensible for compounded GLP-1 programs.
Not universally required for compounded GLP-1, but the Medical Board expects documented synchronous follow-up at clinically appropriate intervals (typically every 90 days during titration).
503A compounding pharmacies serving California patients must hold a current California Board of Pharmacy nonresident sterile compounding permit (if shipping injectables across state lines). 503B outsourcing facilities require separate registration.
Nurse practitioners require a standardized procedure with a supervising physician to prescribe compounded medications. As of 2026, NPs with 100 Practice Authority (per AB 890) have expanded autonomy but compounded GLP-1 protocols still require physician medical director review.
Compounded semaglutide is not a controlled substance, but California enforces strict adverse event reporting for compounded sterile injectables. Schedule II/III controlled substances paired with GLP-1 protocols require DEA-credentialed prescribers.
Specific California statute and regulatory citations operators should reference when structuring a compliant compounded GLP-1 program.
California's prohibition on the unlicensed practice of medicine — the foundation for CPOM enforcement against non-physician control of clinical decisions.
Codifies California's CPOM rule prohibiting general business corporations from practicing medicine or employing physicians for clinical purposes. PC-MSO structures are the compliant alternative.
California Board of Pharmacy regulations on sterile compounding by 503A pharmacies, including patient-specific prescription requirements and documentation standards relevant to compounded GLP-1.
Requires NPs operating below 100 authority to prescribe under standardized procedures co-authored with a supervising physician — relevant to NP-staffed GLP-1 programs.
Take the assessment — tell us your specialty + target states and we'll map your gaps and what onboarding looks like for you.
Authoritative California regulators with jurisdiction over telehealth compounded GLP-1 programs.
Regulatory Information Disclaimer
The telehealth compliance information for California presented on this page is provided for general informational purposes only and should not be construed as legal advice. The telehealth regulatory landscape is evolving rapidly, with state legislatures, medical boards, and federal agencies frequently updating rules, guidance, and enforcement priorities. While TrueEval makes every effort to keep this information current and accurate, we cannot guarantee that all details reflect the very latest regulatory changes at the time of your visit.
We strongly recommend consulting with a qualified healthcare attorney or compliance professional before making business decisions based on this information. For the most current regulatory requirements, refer directly to your state medical board and relevant licensing authorities. Last reviewed: February 2026.
Take the assessment — tell us your specialty + target states and we'll map your gaps and what onboarding looks like for you.